Comparing sugammadex and neostigmine for reversing muscle relaxation during outpatient ERCP
Official title: Comparison of Efficacy of Sugammadex Versus Neostigmine in Reversing Neuromuscular Blocks in Patients Having Outpatient Endoscopic Retrograde Cholangiopancreatography (ERCP). A Randomized, Double-Blinded Trial
Run by The Cleveland Clinic · NCT06136585 · Data updated 2026-11-12
This study is testing whether sugammadex or neostigmine works better to reverse muscle relaxation in adults undergoing a specific outpatient procedure called ERCP.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | The Cleveland Clinic Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | June 1, 2024 |
| Main results expected | October 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | December 15, 2025 |
| Trial ID | NCT06136585 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with ASA physical status 3 or 4 scheduled for elective outpatient ERCP.
✕Probably not a fit
Patients with difficult airways, neuromuscular disorders, end-stage renal disease requiring dialysis, or those who are pregnant or breastfeeding will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial aims to compare the effectiveness of two medications, sugammadex and neostigmine, in reversing muscle relaxation caused by rocuronium in patients undergoing outpatient endoscopic retrograde cholangiopancreatography (ERCP) at the Cleveland Clinic. It is a single-center, assessor-blinded, parallel group randomized trial involving 80 adult patients classified as ASA physical status 3 and 4. Participants will be randomly assigned to receive either sugammadex or neostigmine, with randomization stratified by age and type of procedure. The anesthesiologists will know the group assignments, but patients and outcome assessors will remain blinded.
Why it matters
Potential benefit: If successful, this study could provide a more effective and safer option for reversing neuromuscular blocks in patients undergoing outpatient procedures.
How similar studies have gone: Previous studies have shown varying success with similar approaches, but this specific comparison of sugammadex and neostigmine in the outpatient ERCP setting is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18 years old * American Society of Anesthesiologist physical status 3-4 * Scheduled for outpatient endoscopic retrograde cholangiopancreatography Exclusion Criteria: * Difficult Airway * Neuromuscular Disorders (eg: ALS, Botulism, Myasthenia Gravis, Lambert-eaton syndrome) * End stage renal disease requiring dialysis * Pregnancy or breast-feeding * Allergy to Fentanyl * Allergy to Neuromuscular blocking drugs (eg: rocuronium) * Allergy to Neuromuscular reversal drugs (eg: sugammadex or neostigmine) * Allergy to glycopyrrolate
Where it's running
-
Cleveland Clinic Fairview Hospital
Cleveland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Ryu Komatsu, MD — The Cleveland Clinic
- Study coordinator: Sabry Ayad, MD
- Email: Saayad@ccf.org
- Phone: 216-476-7052
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.